Young American Tennis Player Diagnosed with Hodgkin's
Victoria Duval, the 18-year-old American tennis player who last week lost in the second round at Wimbledon, has announced she has been diagnosed with Hodgkin's lymphoma.
"It is with a heavy heart that I will have to step away from tennis competition for a short period," she said in a statement.
It has been reported that her cancer has been caught in early-stage, that she will begin treatment immediately, and that her doctors believe her prognosis is very good.
Duval learned of her diagnosis following the first round of qualifying at Wimbledon. In that round, Duval beat 29th seeded Sorana Cirstea of Romani. In the next round, she lost to Belinda Bencic of Switzerland.
Duval is no stranger to turmoil. When she was 7, while growing up in Haiti, she and some of her cousins were taken hostage. And in 2010, her father was injured under some collapsed rubble following the major earthquake in that country.
Duval joins fellow young tennis players Ross Hutchins and Alisa Kleybanova in receiving a Hodgkin's diagnosis.
Source: Boston Herald
Photo credit: Christian Mesiano
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
